Glaxo Wellcome Mepron
Executive Summary
Atovaquone suspension approved Jan. 5 for prevention of Pneumocystis carini pneumonia. Mepron is currently marketed for treatment of PCP. NDA 20-500/S-005 was submitted March 5, 1998, and had a user fee deadline of March 5, 1999